{"id":252129,"date":"2020-04-07T00:00:00","date_gmt":"2020-04-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcg0013-biopharma-major-depressive-disorder-dsm-iv-epidemiology\/"},"modified":"2026-03-31T10:45:26","modified_gmt":"2026-03-31T10:45:26","slug":"epidcg0013-biopharma-major-depressive-disorder-dsm-iv-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0013-biopharma-major-depressive-disorder-dsm-iv-epidemiology-mature-markets\/","title":{"rendered":"Major Depressive Disorder (DSM-IV) &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p><abbr title=\"diagnosis-related group\">DRG<\/abbr> Epidemiology\u2019s coverage of major depressive disorder (<abbr title=\"major depressive disorder\">MDD<\/abbr>) (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition\">DSM-IV<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition\">DSM-IV<\/abbr>) for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the major mature pharmaceutical markets.<\/p>\n<p><abbr title=\"diagnosis-related group\">DRG<\/abbr> Epidemiology\u2019s <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition\">DSM-IV<\/abbr>) forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition\">DSM-IV<\/abbr>), how many in each of the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition\">DSM-IV<\/abbr>), how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition\">DSM-IV<\/abbr>) over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the <abbr title=\"diagnosis-related group\">DRG<\/abbr> Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, <abbr title=\"diagnosis-related group\">DRG<\/abbr> Epidemiology forecasts four key <abbr title=\"major depressive disorder\">MDD<\/abbr> (<abbr title=\"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition\">DSM-IV<\/abbr>) patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases.<\/li>\n<li>Diagnosed prevalent cases.<\/li>\n<li>Drug-treated prevalent cases.<\/li>\n<li>Treatment-resistant drug-treated prevalent cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-252129","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-psychiatry","biopharma-product-epidemiology","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252129\/revisions"}],"predecessor-version":[{"id":284632,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252129\/revisions\/284632"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=252129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}